We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05145127
Recruitment Status : Recruiting
First Posted : December 6, 2021
Last Update Posted : November 21, 2022
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:

Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005. Approximately 145 adolescent and adult participants 12 to <75 years of age with severe hemophilia A or moderately severe to severe hemophilia B (defined as FVIII activity <1% or FIX activity ≤2%, respectively) with or without inhibitors are expected to be enrolled in this study during which they will receive prophylaxis (defined as treatment by SC injection of marstacimab). The dosing regimen of marstacimab is 150 mg SC once weekly.

All participants will be provided the PFP for administration of marstacimab in the study. Use of the PFS will be permitted at the investigator's discretion for those participants who have difficulty with administration of the PFP. Additionally, participants will be provided the PFS for use in this study in countries where the PFS is anticipated to be the only presentation available commercially. In addition, an optional, open-label, single arm, substudy using the PFP will be administered to the first approximately 20 participants rolling over from Study B7841005 who agree to participate in the substudy.


Condition or disease Intervention/treatment Phase
Hemophilia A Hemophilia B Drug: PF-06741086 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 145 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN PARTICIPANTS WITH SEVERE HEMOPHILIA A AND B WITH OR WITHOUT INHIBITORS
Actual Study Start Date : November 17, 2021
Estimated Primary Completion Date : July 31, 2030
Estimated Study Completion Date : July 31, 2030

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hemophilia

Arm Intervention/treatment
Experimental: PF-06741086
300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
Drug: PF-06741086
300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
Other Name: marstacimab




Primary Outcome Measures :
  1. Number of subject reporting Adverse Events [ Time Frame: Baseline up to 7 years ]
  2. Number of subjects reporting Serious Adverse Events [ Time Frame: Baseline up to 7 years ]
  3. Incidence and severity of thrombotic events [ Time Frame: Baseline up to 7 years ]
  4. Incidence and severity of thrombotic microangiopathy [ Time Frame: Baseline up to 7 years ]
  5. Number of subjects reporting Disseminated intravascular coagulalopathy/consumption coagulopathy [ Time Frame: Baseline up to 7 years ]
  6. Incidence of clinically significant persistent NAb against marstacimab [ Time Frame: Baseline up to 7 years ]
  7. Incidence and severity of injection site reaction [ Time Frame: Baseline up to 7 years ]
  8. Clinically significant changes in vital signs from baseline [ Time Frame: Baseline up to 7 years ]
  9. Incidence of clinically significant laboratory value abnormalities [ Time Frame: Baseline up to 7 years ]
  10. Incidence of severe hypersensitivity and anaphylactic reactions [ Time Frame: Baseline up to 7 years ]

Secondary Outcome Measures :
  1. Annualized rate of bleeding episodes [ Time Frame: Baseline up to 7 years ]
    Derived for each subject for each treatment period by using the following formula: ABR = number of bleeds requiring treatments/ (days on treatment period / 365.25)

  2. Total coagulation factor product consumption [ Time Frame: Baseline up to 7 years ]
  3. Incidence of joint bleeds [ Time Frame: Baseline up to 7 years ]
  4. Incidence of spontaneous bleeds [ Time Frame: Baseline up to 7 years ]
  5. Incidence of target joint bleeds [ Time Frame: Baseline up to 7 years ]
  6. Incidence of total bleeds (treated and untreated) [ Time Frame: Baseline up to 7 year ]
  7. Percentage of participants with no bleeding episodes [ Time Frame: Baseline up to 7 years ]
  8. Change in joints measured by the HJHS [ Time Frame: Baseline up to 7 years ]
  9. Change in number of target joints per subject from baseline [ Time Frame: Baseline up to 7 years ]
  10. Changes in Health Utilities Measure questionnaire data [ Time Frame: Baseline up to 7 years ]
  11. Changes in Haem-A-QoL questionnaire data for participants ≥17 years of age [ Time Frame: Baseline up to 7 years ]
  12. Changes in Haemo-QoL questionnaire data for participants 12 to <17 years of age [ Time Frame: Baseline up to 7 years ]
  13. Total bypass product consumption [ Time Frame: Baseline up to 7 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 74 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Male participants only
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All participants will have a minimum body weight of 35 kg
  • Participants have successfully completed participation in study B7841005, defined as did not require "Early Termination" from study B7841005

Exclusion Criteria:

  • Previous or current treatment for or history of coronary artery disease, venous or arterial thrombosis (CTCAE Grade >3), or ischemic disease (except catherter-associated thrombosis)
  • Abnormal renal function as defined by eGFR <30 mL.min/1.73 m(2)
  • Known planned surgical procedure during the planned study period
  • Unstable hepatic function as determined by the Investigator clinical assessment and review of the participant's most recent laboratory results, which would make the participant inappropriate for the study
  • For participants known to be HIV+, worsening disease status as determined by the Investigator clinical assessment and review of participant's most recent laboratory results, to include recent locally available CD4 count (if available), which would make the participant inappropriate for the study
  • Regular, concomitant therapy with immunomodulatory drugs (eg, IVIG, and routine systemic corticosteroids, rituximab)
  • Ongoing or planned use of immune tolerance induction or prophylaxis with FVIII or FIX replacement during the study
  • Participation in other study involving investigational drug(s) or investigational vaccine(s) within 30 days or 5 half-lives prior to or during study participation, with the exception of participation in study B7841005
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the Investigator, and their respective family members

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05145127


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Show Show 26 study locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT05145127    
Other Study ID Numbers: B7841007
PHASE 3 ANTI-TFPI OLE ( Other Identifier: Alias Study Number )
First Posted: December 6, 2021    Key Record Dates
Last Update Posted: November 21, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Factor VIII Inhibitor
Factor IX Inhibitor
PF-06741086
Marstacimab
Anti-TFPI
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked